tradingkey.logo
tradingkey.logo
Search

Niagen Bioscience Inc

NAGE
Add to Watchlist
3.705USD
-0.095-2.51%
Market hours ETQuotes delayed by 15 min
294.36MMarket Cap
15.86P/E TTM

Niagen Bioscience Inc

3.705
-0.095-2.51%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-2.51%

5 Days

-11.58%

1 Month

-21.01%

6 Months

-46.08%

Year to Date

-41.75%

1 Year

-63.32%

Key Insights

Niagen Bioscience Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 69 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.60.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Niagen Bioscience Inc's Score

Industry at a Glance

Industry Ranking
69 / 382
Overall Ranking
177 / 4482
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Niagen Bioscience Inc Highlights

StrengthsRisks
Niagen Bioscience, Inc., formerly Chromadex Corp., is a global bioscience company. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. The Company’s Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers and distributors and offers NAD+ test kits exclusively to healthcare practitioners. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and United States FDA-registered 503B outsourcing facilities, respectively. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 54.87% year-on-year.
Fairly Valued
The company’s latest PE is 16.27, at a medium 3-year percentile range.
Held by Invesco
Star Investor Invesco holds 19.64K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.03.

Analyst Rating

Based on 5 analysts
Buy
Current Rating
12.600
Target Price
+235.11%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Niagen Bioscience Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Niagen Bioscience Inc Info

Niagen Bioscience, Inc., formerly Chromadex Corp., is a global bioscience company. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. The Company’s Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers and distributors and offers NAD+ test kits exclusively to healthcare practitioners. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and United States FDA-registered 503B outsourcing facilities, respectively. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
Ticker SymbolNAGE
CompanyNiagen Bioscience Inc
CEOFried (Robert N)
Websitehttps://www.niagenbioscience.com/
KeyAI